α -Synuclein Modification in an ALS Animal Model

Area of Science:

• Neuroscience
• Toxicology
• Biochemistry

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by progressive paralysis, often linked to mutations in Cu/Zn-superoxide dismutase 1 (SOD1).
• Overexpression of mutant SOD1 in transgenic mice leads to paralysis and protein aggregate accumulation in the central nervous system.
• Bee venom (BV), derived from honeybees, is traditionally used for inflammatory conditions.

Purpose of the Study:

• To investigate the effects of bee venom (BV) on misfolded protein aggregates, specifically alpha-synuclein.
• To assess the impact of BV on ubiquitin-proteasomal activity in a mouse model of ALS (hSOD1(G93A)).

Main Methods:

• Bee venom (BV) was administered to 98-day-old hSOD1(G93A) transgenic mice.
• Levels of detergent-insoluble polymerization and phosphorylation of alpha-synuclein were analyzed.
• Proteasomal activity in the brainstems of treated mice was evaluated.

Main Results:

• BV treatment significantly reduced detergent-insoluble polymerization and phosphorylation of alpha-synuclein in hSOD1(G93A) mice.
• Phosphorylated and nitrated alpha-synuclein levels were notably decreased in the spinal cords and brainstems of BV-treated mice.
• Reduced proteasomal activity was observed in the brainstems of BV-treated symptomatic hSOD1(G93A) mice.

Conclusions:

• Bee venom (BV) treatment appears to attenuate the dysfunction of the ubiquitin-proteasomal system in a symptomatic hSOD1(G93A) ALS mouse model.
• These findings suggest that BV may offer a therapeutic strategy to slow motor neuron loss associated with misfolded protein aggregates in ALS.